A share price of Caribou Biosciences Inc [CRBU] is currently trading at $0.87, up 1.72%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The CRBU shares have gain 13.92% over the last week, with a monthly amount drifted -11.28%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Caribou Biosciences Inc [NASDAQ: CRBU] stock has seen the most recent analyst activity on June 03, 2024, when Evercore ISI downgraded its rating to a In-line and also revised its price target to $3 from $13. On October 31, 2023, Evercore ISI initiated with a Outperform rating and assigned a price target of $13 on the stock. Truist started tracking the stock assigning a Buy rating and suggested a price target of $23 on July 11, 2023. RBC Capital Mkts initiated its recommendation with a Outperform and recommended $22 as its price target on February 18, 2022. Oppenheimer started tracking with a Outperform rating for this stock on December 01, 2021, and assigned it a price target of $36. In a note dated November 30, 2021, H.C. Wainwright initiated an Buy rating and provided a target price of $28 on this stock.
Caribou Biosciences Inc experienced fluctuations in its stock price throughout the past year between $0.66 and $4.42. Currently, Wall Street analysts expect the stock to reach $3 within the next 12 months. Caribou Biosciences Inc [NASDAQ: CRBU] shares were valued at $0.87 at the most recent close of the market. An investor can expect a potential return of 244.83% based on the average CRBU price forecast.
Analyzing the CRBU fundamentals
Trailing Twelve Months sales for Caribou Biosciences Inc [NASDAQ:CRBU] were 9.99M which represents -41.62% decline. Gross Profit Margin for this corporation currently stands at 0.84% with Operating Profit Margin at -16.67%, Pretax Profit Margin comes in at -14.92%, and Net Profit Margin reading is -14.92%. To continue investigating profitability, this company’s Return on Assets is posted at -0.48, Equity is -0.5 and Total Capital is -0.59. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.1.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.8111 points at the first support level, and at 0.7478 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.9377, and for the 2nd resistance point, it is at 1.0010.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Caribou Biosciences Inc [NASDAQ:CRBU] is 7.16. As well, the Quick Ratio is 7.16, while the Cash Ratio is 0.53. Considering the valuation of this stock, the price to sales ratio is 8.14, the price to book ratio is 0.32.
Transactions by insiders
Recent insider trading involved Haurwitz Rachel E., President and CEO, that happened on Mar 14 ’25 when 20000.0 shares were purchased. Chief Legal Officer, MCCLUNG BARBARA G completed a deal on Feb 21 ’25 to sell 3564.0 shares. Meanwhile, Chief Business Officer Khan Ruhi Ahmad sold 3564.0 shares on Feb 21 ’25.
